Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Deqing Han"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Meningioma, the most prevalent intracranial tumor, possesses a significant propensity for malignant transformation. Circular RNAs (circ-RNAs), a class of non-coding RNAs, have emerged as crucial players in tumorigenesis. This stud
Externí odkaz:
https://doaj.org/article/3c4ee4f26d0a42b4923f50bcb6eed796
Autor:
Xiaopeng Zhu, Sian Pan, Rui Li, Zebo Chen, Xingyun Xie, Deqing Han, Shengqing Lv, Yongkai Huang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma multiforme (GBM) is the most aggressive malignant primary central nervous system tumor. Although surgery, radiotherapy, and chemotherapy treatments are available, the 5-year survival rate of GBM is only 5.8%. Therefore, it is imperative
Externí odkaz:
https://doaj.org/article/bad2789f18f24cb785ec52213388fdc6
Publikováno v:
Frontiers in Neuroscience, Vol 15 (2021)
In recent years, neuroimaging evidence shows that the brains of Parkinson disease (PD) with impulse control disorders (ICDs) patients have functional disconnection changes. However, so far, it is still unclear whether the topological organization is
Externí odkaz:
https://doaj.org/article/5348e15e16e5454f8be3dd347021b8ac
Autor:
Xiaopeng Zhu, Xun Chen, Zhao Liu, Bihui Yang, Yuxiang Zhou, Sian Pan, Yongkai Huang, Deqing Han, Yiqian Zeng, Chao Liu
Publikováno v:
Journal of Oncology. 2023:1-13
Background. Aging is recognized as a main tumor risk factor, and thus aging has become a field of interest in the tumor research field. Glioblastoma multiforme represents the most typical primary malignant intracranial tumor, particularly in the elde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a31b61f4881fac0ed8c309ba84b3456
https://doi.org/10.1155/2023/9220547
https://doi.org/10.1155/2023/9220547
Autor:
Zhihua Qiu, Deqing Han, Yongkai Huang, Qinghui Huang, Tao Chen, Chenzhi Zhou, Wen Yuan, Chao Liu
Publikováno v:
Gene. 576:22-27
The metabolic program of cancer cells is significant different from the normal cells, which makes it possible to develop novel strategies targeting cancer cells. Mevalonate pathway and its rate-limiting enzyme HMG-CoA reductase (HMGCR) have shown imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd09272de86b127e40667f72163782d7
https://doi.org/10.1016/j.gene.2015.09.067
https://doi.org/10.1016/j.gene.2015.09.067